Poxel to Sell PXL770 to Scynexis for up to $196mln, Shares Rise

Poxel SA has agreed to sell its drug candidate PXL770 to Scynexis for up to $196 million. The deal includes an upfront payment of $8 million, with additional payments tied to development and commercial milestones. PXL770 targets autosomal dominant polycystic kidney disease, with a Phase 2 study expected to begin in Q4 2026. Poxel plans to focus on its core pipeline and pursue new partnerships. Scynexis is a biotech company focused on severe and rare diseases.